Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306850 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
A Phase 2 study, sponsored by St. Louis University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02306850 is a Phase 2 study that has completed, run by St. Louis University. The registered enrollment target is 10 participants.
The verdict
NCT02306850, a Phase 2 study, has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body. Eligible participants include those who have not received any systemic melanoma therapies (i.e. participants do not have to fail ipilimumab or BRAF inhibitor) and those who have failed all available systemic options (if the participant meets other inclusion / exclusion criteria).
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02306850
The ClinicalTrials.gov registry entry for NCT02306850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02306850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02306850 about?
NCT02306850 is a clinical study titled "Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma". This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body. Eligible participants include those who have not received any systemic melanoma therapies (i...
What is the current status of trial NCT02306850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2018-06-08.
What interventions are being tested in trial NCT02306850?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02306850?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.